Didn't miss the boat - have been a LT Holder.
You are right "CDY is a really good story, but ignored until today like most small cap biotechs".
As far as I can ascertain, Wise-Owl did not include the potential for hair loss revenue. It only included "Cellmid's immediate product development focus and does not take into account the substantial product pipeline both in the therapeutic and diagnostic business streams". IMO 13.5c valuation is way too conservative.
Today's announcement may also bring forward or clinch more lucrative licensing deals as well.
up 215% today - whos missing the boat?, page-15
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| AN1 (ASX) Chart |
Day chart unavailable